arXiv:2608.30912v1 Announce Type: new Abstract: Artificial intelligence (AI) and natural language processing (NLP) are increasingly used to extract, integrate, and interpret biomedical knowledge rele...
OpenMTB‑Audit is an open‑source benchmark that tests large language models on 500 synthetic non‑small cell lung cancer cases, covering five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. The study found that all eight tested LLMs over‑refused Partially Supported recommendations, collapsing labels to achieve high safety scores. A deterministic seven‑module framework, MTB‑AuditAgent, was introduced to reduce over‑refusal to 6.7% and reach 91.2% accuracy, while an oncologist annotation study highlighted disagreement around the boundary between information sufficiency and treatment optimization.
arXiv:2608.28974v1 Announce Type: new Abstract: Clinically relevant oncology information is distributed across heterogeneous, longitudinal documentation, creating substantial abstraction burden and r...
Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological asses...
The article presents a new semantic model for representing scientific evidence, specifically tailored to genetics, that extends existing standards by adding fine‑grained, domain‑specific structure. It aligns with FHIR Evidence and SEPIO, incorporates a compact vocabulary validated by SHACL, and was tested in a human‑AI annotation pilot on six genetics papers, producing 28 evidence items and 95 source‑anchored assertions. The authors argue that this model advances trustworthy, AI‑ready infrastructure for variant interpretation by providing a reference data model and validation schema for genetic evidence.
arXiv:2512. 03296v2 Announce Type: replace-cross Abstract: Cancer treatment outcomes are influenced not only by clinical and demographic factors but also by the collaboration of healthcare teams.
arXiv:2608.22085v1 Announce Type: new Abstract: Synthetic clinical data generation with large language models addresses the scarcity that limits cancer staging research, but oncology hallucinations a...
arXiv:2608.28820v1 Announce Type: new Abstract: Computational pathology (CompPath) is transforming medicine by leveraging artificial intelligence (AI) algorithms to support diagnosis, prognosis, and...
arXiv:2510. 17532v2 Announce Type: replace-cross Abstract: Predicting cancer treatment outcomes requires models that are both accurate and interpretable, particularly in the presence of heterogeneous clinical data.
BiomedXPro is an evolutionary framework that uses a large language model to automatically generate a diverse set of interpretable, natural‑language prompt pairs for disease diagnosis with biomedical vision‑language models. It addresses the lack of transparency in existing prompt optimization methods by producing prompts that are both understandable and aligned with clinically significant features. Experiments on multiple biomedical benchmarks show that BiomedXPro outperforms state‑of‑the‑art prompt‑tuning techniques, especially in few‑shot, data‑scarce scenarios.
arXiv:2609.01202v1 Announce Type: cross Abstract: Clinical trials are essential for advancing cancer care and drug development, but many fail because of insufficient patient enrollment. While there i...
LUCAID is an agentic multimodal AI system designed for precision lung cancer pathology, integrating nine modules that cover the entire routine workflow—from quality control and tumor detection to histological subtyping, microenvironment profiling, cellularity quantification, and biomarker scoring (PD‑L1, MET, TROP‑2). The system generates automated structured reports and allows interactive querying of module outputs. In prospective clinical validation, LUCAID achieved 93.0% concordance with an expert‑panel reference standard for clinically actionable decisions, outperforming five experienced thoracic pathologists who ranged from 68.3% to 81.1% concordance.